

1 **Time from treatment initiation to HIV viral suppression in public care**  
2 **facilities in Brazil: a nationwide linked databases cohort**

3

4 Maria Ines Battistella Nemes<sup>1#</sup>, Ana Paula Sayuri Sato<sup>2^</sup>, Barbara Reis-Santos<sup>1&</sup>, Ana  
5 Maroso Alves<sup>1\*</sup>, Felipe Parra do Nascimento<sup>1"</sup>, Bruce Agins<sup>3"</sup>

6

7 <sup>1</sup> Department of Preventive Medicine, School of Medicine, University of São Paulo, São Paulo, São  
8 Paulo, Brazil.

9 <sup>2</sup> Department of Epidemiology, School of Public Health Universidade de São Paulo, University of São  
10 Paulo, São Paulo, São Paulo, Brazil.

11 <sup>3</sup> Institute for Global Health Sciences, Division of Epidemiology, University of California, San Francisco,  
12 California, United States of America

13

14 #Conceptualization, Supervision, Investigation, Methodology, Data curation, Writing – original draft,  
15 Writing – review & editing

16 ^ Conceptualization, Formal analysis, Methodology, Validation, Visualization, Writing – original draft,  
17 Writing – review & editing

18 \*Conceptualization, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review &  
19 editing

20 "Formal analysis, Visualization, Writing – original draft, Writing – review & editing  
21 & Visualization, Writing – original draft, Writing – review & editing

22 "Writing – original draft, Writing – review & editing

23

24 **Corresponding author**

25 e-mail: [mibnemes@usp.br](mailto:mibnemes@usp.br) (MIBN)

26

27

28

29

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 31 **Abstract**

32 **Objectives:** To analyze the time between antiretroviral therapy (ART) initiation and  
33 the first HIV viral load (VL) test <40 copies—time to suppression (TS)—in a cohort of  
34 persons aged  $\geq 15$  years, between 2015-2018 in outpatient HIV care facilities of the  
35 Brazilian Unified Health System, as well as to analyze whether individual and facility  
36 characteristics accelerate or delay TS.

37 **Methods:** This was a cohort study with data from a linkage of national HIV  
38 databases, following a previously published procedure. Two types of variables were  
39 examined: individual-level (sex, age group, race/skin color, education, baseline  
40 CD4 cell count and VL, initial ART regimen, adherence, ART regimen change and  
41 number of VL tests until suppression) and facility-level (national and metropolitan  
42 region, caseload). Multilevel parametric accelerated failure time survival models were  
43 used. Fixed and random effects were analyzed through null, sociodemographic,  
44 combined sociodemographic and clinical, and facility-related variables, adjusted for  
45 the number of VL tests until suppression. Likelihood, interquartile range, and  
46 proportion of change in variance were used for comparisons.

47 **Results:** Of 132,540 participants, 89.4% (114,696) achieved viral suppression:  
48 20.8% within three months, and 56.4% within six months. Median TS was 161 days,  
49 varying from 31 to 1,426 days, depending on the time interval between initiation and  
50 VL testing. Among those who had VL testing within 66 days, median TS was 55 days.  
51 All individual and facility-related variables were associated with TS, explaining the  
52 16.2% and 13.2% variability, respectively.

53 **Conclusions:** This was the first Brazilian nationwide cohort to analyze TS. It is also  
54 one of the largest operational cohorts globally to assess healthcare facility  
55 characteristics. The findings indicated that both individual and facility-related  
56 characteristics contribute to TS. Strengthening VL monitoring should be included as  
57 part of a coordinated effort to improve the quality of care provided for people living with  
58 HIV/AIDS in Brazil.

## 59 **Introduction**

60 The clinical and public health benefits of HIV viral load suppression (VS) through  
61 combination antiretroviral therapy (ART) are well-established, supported by robust  
62 scientific evidence[1-4] which forms the basis for policies and strategies that aim to  
63 engage the international community, governments, and civil society in achieving and  
64 maintaining VS targets. Cascade-based official reports from HIV national programs  
65 [5,6] compile indicators that are immediately useful for healthcare professionals, HIV  
66 care facility managers, and system managers[7,8]. These indicators are, however,  
67 limited by their cross-sectional design, as they assess the VS proportion of the group  
68 of persons in care within a fixed time interval (usually six, 12, or 24 months) between  
69 ART initiation and VS achievement, without considering temporal evolution[9].  
70 Acknowledging these limitations, researchers have advocated that the parameter used  
71 by HIV programs to monitor ART success be time to VS[10-14].

72 With widespread use of integrase inhibitors [9], an increase has been seen in studies  
73 examining time to VS continuously[15-20]. As associated factors, a significant portion  
74 of these studies analyze individual characteristics, whereas fewer of them also analyze  
75 care facility characteristics[20-23].

76 Up to the time of writing this paper, we identified only one population-based cross-  
77 sectional study in Brazil that assessed the median time between ART initiation and  
78 VS, conducted from 2004 to 2018 in one Brazilian state[24]. No study including care  
79 facility characteristics in its analysis was, however, found.

80 This article aimed to analyze the time between ART initiation and first VS in a cohort  
81 of persons living with HIV/AIDS (PLWHA) who initiated ART between 2015 and 2018  
82 in outpatient HIV care facilities of the Brazilian Unified Health System (SUS). A further  
83 objective was to analyze whether individual characteristics and healthcare facility  
84 characteristics accelerate or delay time to VS.

## 85 **Materials and methods**

### 86 **Study design**

87 This was an observational longitudinal study including PLWHA aged  $\geq 15$  years who  
88 are participants in the Qualiaids-Brazil Cohort.

### 89 **Context**

90 In Brazil, the establishment of the national program for STD/AIDS in 1986[25]  
91 prompted the implementation of hospital and outpatient facilities for the treatment of  
92 people with AIDS, mostly within pre-existing structures of the public health system[26],  
93 which officially became the SUS[27] in 1988. The spread of AIDS in the country and  
94 the introduction of ART in 1996, which turned HIV disease into a chronic condition, led  
95 to a significant expansion in the number of outpatient facilities, reaching approximately  
96 1,300 today[28]. These facilities are the exclusive providers of ART medication for  
97 approximately 852,000 people. Clinical monitoring of PLWHA can be carried out within

98 the public or private healthcare system. According to the cohort database, it has been  
99 estimated that 69% of PLWHA received outpatient monitoring through SUS  
100 facilities[28,29].

## 101 **Study population**

102 The Qualiaids-Brazil Cohort comprises PLWHA who received treatment at SUS  
103 facilities that participated as respondents in a national survey regarding facility  
104 characteristics (Qualiaids Survey)[30-34]. PLWHA aged  $\geq 15$  years were included if  
105 they had their first ART dispensation between 2015 and 2018, a CD4 test conducted  
106 between 120 days before and 30 days after the first ART dispensation, and at least  
107 two viral load (VL) test results. The exclusion criteria considered inconsistencies in  
108 PLWHA data among the data sources used. Further information on the construction  
109 of the database and the profile of the Qualiaids-Brazil Cohort can be obtained from a  
110 previous publication[29].

111 For this study, only PLWHA who were in treatment for more than 30 days were  
112 included[35]. This was due both to the inability to assess treatment effect for very early  
113 suppressions and the possibility of delays in recording the first dispensation date.  
114 Those who had their last VL test in the SUS before their first ART dispensation were  
115 excluded.

## 116 **Follow-up**

117 The date of the first medication dispensation was defined as the initiation of ART, and  
118 the date of the last VL test was set as the final follow-up date. Deaths and loss to  
119 follow-up were classified as censoring events. The mortality data comprised only those

120 deaths attributed to HIV-related causes[29]. Loss to follow-up was attributed to  
121 individuals who went more than 100 days without picking up medication or having VL  
122 tests until the final follow-up date of the cohort (December 31, 2018)[29].  
123 Administrative censoring referred to individuals who did not achieve VS by the end of  
124 the follow-up period.

## 125 **Study variables**

126 The dependent variable was the time from treatment initiation to VS, defined as the  
127 number of days elapsed between the date of the first ART dispensation and the date  
128 of the first VL <40 copies/mL after ART initiation. The independent variables included  
129 data on individuals and treatment facilities.

130 The following sociodemographic characteristics of individuals were included: *sex*  
131 (female; male), *age group* (15-19; 20-29; 30-39; 40-49; 50-59; ≥60 years), *race/skin*  
132 *color* (white; black; yellow; mixed-race; indigenous), and *education level* (none; 1-3; 4-  
133 7; 8-11; ≥12 years). For the variables *race/skin color* and *education level* 7.3% and  
134 18.6% of entries were missing data respectively. Therefore, imputation was performed  
135 to reduce potential biases in the analyses by using Stata 15's *mi impute mlogit* library,  
136 which employs a multinomial logistic regression model for imputation of nominal  
137 variables. The variable *transmission category* was excluded due to the high proportion  
138 of missing records (34.2%) in the original database.

139 Among individual clinical characteristics, *baseline CD4 lymphocyte count* showed  
140 considerable variation within the interval between the date of the test and treatment  
141 initiation, as has been reported elsewhere in the literature [36,37]. We thus decided to  
142 consider as baseline the CD4 lymphocyte count performed between six months before

143 and 30 days after the treatment initiation date (<200; 200-349; 350-499; ≥500  
144 cells/mm<sup>3</sup>). The remaining clinical variables included were: *initial VL count* (≤100,000;  
145 >100,000 copies/mL) *and occurrence of active tuberculosis episode until the first VS*  
146 (no; yes). Regarding treatment, the variable *initial therapeutic regimen* comprised ART  
147 medications specified in the clinical protocol of the period: preferred regimens – non-  
148 nucleoside reverse transcriptase inhibitor + 1 integrase inhibitor (NNRTI+1INI) and  
149 nucleoside reverse transcriptase inhibitors + 1 non-nucleoside reverse transcriptase  
150 inhibitor (2NRTI+1NNRTI); special regimens authorized by regional technical  
151 chambers and unauthorized regimens[38].


152 Additionally, the following variables were included: *change in therapeutic regimen until*  
153 *VS* (no; yes), *adherence to treatment until the first VS*, measured by the Medication  
154 Possession Ratio - MPR (<80%; 80-94%; ≥95%), and the *number of VL tests*  
155 *conducted until VS*.

156 The variables regarding treatment facility characteristics were: *facility location*  
157 *according to geographical region* (North; Northeast; Central-West; South; Southeast),  
158 *metropolitan region* (no; yes), and *total number of PLWHA who initiated ART at the*  
159 *facility between 2015-2018* (≤50; 51-500; >500).

## 160 **Data analysis**

161 The dependent variable was the distribution of the time from treatment initiation to VS,  
162 for which Normal, Log-Normal, Weibull, Exponential, and Gamma distributions were  
163 tested[39]. The Log-Normal distribution showed the best fit to the data. We therefore  
164 decided to use a parametric multilevel accelerated failure time survival model with a  
165 Log-Normal distribution for the analysis of cohort data[40,41].

166 Initially, the absolute and relative frequencies of the qualitative variables were  
167 examined, and measures of central tendency and dispersion were calculated for the  
168 dependent (quantitative) variable. Subsequently, bivariate analyses were conducted  
169 between the dependent variable and each individual and facility-related variable.  
170 Finally, these variables were analyzed in multiple hierarchical models. The two levels  
171 of aggregation in the models (individual and facility-related) and the hierarchy of  
172 variables were defined based on the theoretical model presented in Figure 1.



173  
174 **Fig 1. Theoretical model of clinical outcome production in HIV infection**  
175 **treatment**  
176 (a) Ministry of Health systems for continuous information recording: SINAN, SIM,  
177 SICLOM, SISCEL. (b) 2017 and 2023 nationwide Qualiaids surveys

178 Four models were constructed for the multiple analysis, aiming to measure the fixed  
179 and random effects of the variables at each level. Based on the null model, individual  
180 variables were included in the following sequence: sociodemographic characteristics,  
181 disease severity, and treatment. The model relative to treatment facilities included only



182 the block of facility-related variables. Comparisons between the models were  
183 conducted using likelihood, interquartile range, and the proportion of change in  
184 variance. The results were presented as time ratios (TR) and their respective 95%  
185 confidence intervals (95% CI). The significance level used for all analyses was 5%.

186 For the characterization of random effects, the four analyzed models were compared  
187 in terms of random variance (standard error-SE), intraclass correlation coefficient  
188 (ICC), log likelihood, and proportional change in variance (PCV)[42-45].

189 The PCV, at the contextual level, measures the variation of time to VS across  
190 healthcare facilities and is defined as[42,43,45]:

$$191 \quad PCV = \frac{\text{Random variance of the null model} - \text{random variance of the final model}}{\text{Random variance of the null model}}$$

192 Contextual differences in time to VS can be attributed to random effects or differences  
193 in individual composition of the facilities in terms of sociodemographic factors, disease  
194 severity, or treatment initiation of the patients. Therefore, the PCV was calculated by  
195 comparing the null model with the other models that included only individual variables  
196 (models 1 and 2) and only facility-related variables (model 3).

197 The ICC is the proportion of the total variance of time to VS among treatment facilities  
198 that is attributed to facility variability; in other words, it measures the heterogeneity of  
199 time to VS attributed to differences between facilities, and is calculated for each model  
200 using the formula[44]:

$$201 \quad ICC = \frac{\text{Random variance}}{\text{Random variance} + \text{individual variance}}$$

202 As detected in observational[24,46-50] studies, there has been variation in adherence  
203 to the VL monitoring protocol, which may affect the estimates[46-51]. To minimize this  
204 limitation, all models were adjusted for the number of VL tests received by the  
205 individual.

206 Additionally, a sensitivity analysis was conducted by replicating the models with the  
207 inclusion of the variable *transmission category*, using the subset of individuals with  
208 complete information for this variable (Supplementary Table 2), and without  
209 adjustment for the number of VL tests received (Supplementary Table 3). All analyses  
210 were performed using Stata 15.0's *mestreg* package.

## 211 **Ethical considerations**


212 The project was approved by the Ethics Committee on Research on Human Beings of  
213 the USP School of Medicine on January 23, 2020 (CAAE: 27659220.3.0000.0065;  
214 Opinion: 3.807.435), following the recommendations of Resolution No. 466 of 2012  
215 from the Brazilian National Health Council. The data was sent to the research team on  
216 May 10, 2020. There were no variables or information that could identify the individuals  
217 in the data set received.

## 218 **Results**

219 The Qualiaids-Brazil Cohort comprises 132,540 PLWHA who initiated ART in Brazil  
220 between January 1, 2015, and December 31, 2018. For this study, considering  
221 eligibility criteria, 128,360 PLWHA were included who had been in treatment for more  
222 than 30 days and received at least one VL test after starting ART. A total of 2,544  
223 (1.9%) individuals who had been in treatment for fewer than 30 days, and 1,636 (1.2%)  
224 individuals who did not receive a VL test before the first ART dispensation were

225 excluded. The censoring events were as follows: 1,496 (1.1%) deaths, 3,838 (2.9%)  
226 losses to follow-up, and 10,988 (8.3%) administrative censorings[29].

227 The distribution of time to VS is shown in Figure 2. Of the PLWHA considered in this  
228 study, 89.4% (114,696) achieved VS, with 20.8% (23,801) reaching it within 3 months  
229 after treatment initiation, 56.4% (64,636) within 6 months, and 87.5% (100,408) within  
230 12 months.




231 **Fig 2. Distribution of time to VS, in days, Qualiaids-Brazil Cohort, 2015-2018 (N**  
232 **= 128,360)**

233  
234  
235 The median time to VS for all included individuals was 161 days, ranging from 31 to  
236 1,426 days, depending on the time interval between treatment initiation and the control  
237 VL test. Shorter intervals resulted in smaller medians (Supplementary Table 1).

238 Regarding the distribution of individual characteristics of the participants, higher  
239 proportions of PLWHA were identified as male (69.8%), aged 20-39 years (64.3%),  
240 with >8 years of schooling (62.8%), and of race/skin color brown or black (54.6%). A

241 total of 26% of participants had an initial CD4 count <200 cells/mm<sup>3</sup>, whereas initial  
242 VL >100,000 copies/mL was observed in 8.2% of participants. The initial therapeutic  
243 regimen was 2NRTI + 1NNRTI for 61.8% of participants; 3.2% changed their  
244 therapeutic regimen before the first VS. 42.5% of participants experienced an episode  
245 of tuberculosis before the first VS. 42.5% of participants had treatment adherence  
246 rates of ≥95%.

247 Regarding the treatment facilities, Figure 3 shows the distribution of the 941 included  
248 facilities and of PLWHA monitored in them, according to geographic region and  
249 location in metropolitan areas. The Southeast region accounted for most facilities  
250 (59.0%) and PLWHA (41.2%). There was a predominance of facilities located in capital  
251 cities or metropolitan regions (66.2%) and facilities assisting 51-500 individuals who  
252 started ART during the period (49.0%).



Number of facilities ranked by size	Central-West		Northeast		North		Southeast		South		Total	
	n	%	n	%	n	%	n	%	n	%	n	%
Up to 50 persons	6	15.0	33	26.8	8	17.8	306	55.1	44	24.7	397	42.2
51 to 500 persons	27	67.5	72	58.5	28	62.2	219	39.5	115	64.6	461	49.0
More than 500 persons	7	17.5	18	14.6	9	20.0	30	5.4	19	10.7	83	8.8
<b>Total</b>	<b>40</b>	<b>100.0</b>	<b>123</b>	<b>100.0</b>	<b>45</b>	<b>100.0</b>	<b>555</b>	<b>100.0</b>	<b>178</b>	<b>100.0</b>	<b>941</b>	<b>100.0</b>

253

254 **Fig 2. SUS HIV treatment facilities and number of individuals included in the cohort**  
 255 **who initiated ART in 2015-2018, categorized by macro-region of the country.**  
 256 **Qualiaids-Brazil Cohort, 2022 (N=941)**

257

258 Table 1 shows the observed proportions of individual characteristics and the bivariate  
 259 analyses between the dependent variable and each of the individual variables  
 260 (sociodemographic, clinical, and treatment-related).

261 **Table 1. Descriptive analysis and bivariate analysis of the time from treatment**  
 262 **initiation to VS, according to individual variables. Qualiaids-Brazil Cohort,**  
 263 **2015-2018 (N = 128,360)**

Variable	Total	%	Bivariate
----------	-------	---	-----------

			Suppression*	Time Ratio	LT	HT
<b>Sex</b>						
Male	89,586	69.8	89.5	ref		
Female	38,774	30.2	88.9	0.93	0.93	0.94**
<b>Age group (in years)</b>						
15-19	5,761	4.5	87.1	1.04	1.02	1.07**
20-29	44,823	34.9	89.7	1.01	0.99	1.02
30-39	37,672	29.4	88.8	1.03	1.02	1.05**
40-49	23,214	18.1	89.2	1.03	1.02	1.05**
50-59	12,081	9.4	90.4	ref		
≥60	4,809	3.8	91.3	0.98	0.96	1.01
<b>Race/skin color</b>						
White	57,183	44.5	91.0	ref		
Black	14,181	11.1	87.8	1.04	1.02	1.05**
Yellow	953	0.7	88.9	1.03	0.98	1.09
Brown	55,772	43.5	88.2	1.04	1.03	1.05**
Indigenous	271	0.2	79.3	1.22	1.11	1.34**
<b>Education (in years of schooling)</b>						
None	2,278	1.8	86.7	1.18	1.14	1.22**
1-3	11,132	8.7	85.6	1.21	1.19	1.24**
4-7	34,298	26.7	86.9	1.17	1.16	1.19**
8-11	52,042	40.5	90.1	1.07	1.06	1.08**
≥12	28,610	22.3	92.5	ref		
<b>Initial therapeutic regimen</b>						
Preferred regimen (2017-2018: NNRTI+1INI)	48,410	37.7	89.6	ref		
Preferred regimen (2015-2016: 2NRTI + 1NNRTI)	79,288	61.8	89.3	1.54	1.53	1.55**
Authorized special regimens	118	0.1	83.1	1.39	1.21	1.60**
Unauthorized regimens	544	0.4	85.7	1.48	1.39	1.58**
<b>Initial CD4 lymphocyte count (cells/mm<sup>3</sup>)</b>						
<200	33,327	26.0	82.7	1.33	1.31	1.35**
200-349	25,054	19.5	89.1	1.14	1.13	1.15**
350-499	26,329	20.5	91.6	1.07	1.05	1.08**
≥500	43,650	34.0	93.2	ref		
<b>Initial VL count (copies/mL)</b>						
≤100,000	117,864	91.8	91.9	ref		
>100,000	10,496	8.2	82.6	1.39	1.38	1.40**
<b>Active tuberculosis episode until suppression</b>						
No	122,014	95.1	90.2	ref		
Yes	6,346	4.9	72.9	1.45	1.42	1.48**
<b>Therapeutic regimen change before suppression</b>						
No	124,305	96.8	89.0	ref		
Yes	4,055	3.2	100.0	1.45	1.42	1.49**
<b>Adherence</b>						
≥95%	54,618	42.5	92.6	Ref		
80-95%	66,334	51.7	89.4	1.40	1.39	1.41**
<80%	7,408	5.8	65.4	2.17	2.12	2.21**

264 \* Chi-square p<0.05 for all variables \*\*P≤0.001

265 Table 2 shows the bivariate analysis between the dependent variable and each of the  
 266 facility-related variables.

267 **Table 2. Bivariate analysis of the time between treatment initiation and VS,**  
 268 **according to facility-related variables. Qualiads-Brazil Cohort, 2015-2018 (N =**  
 269 **128,360)**

270

Variable	TR (95% CI)
<b>Geographic region</b>	
Central-West	1.10[1.03;1.18]
North	1.13[1.06;1.21]
Northeast	1.14[1.09;1.19]
South	0.99[0.96;1.04]
Southeast	Ref
<b>Facility location (municipality)</b>	
Metropolitan region	Ref
Other	1.09[1.05;1.12]
<b>Number of patients served</b>	
≤50	1.15[1.09;1.21]
51-500	1.03[0.98;1.07]
>500	Ref

271

272 The bivariate analysis showed that PLWHA who received care in facilities in the North  
 273 (TR = 1.13; 95% CI: 1.06; 1.21), Northeast (TR = 1.14; 95% CI: 1.09; 1.19), and  
 274 Central-West (TR = 1.10; 95% CI: 1.03; 1.18) regions had a longer time to VS  
 275 compared to those in the Southeast. This finding was also observed for PLWHA  
 276 treated in facilities located outside the metropolitan region (TR = 1.09; 95% CI: 1.05;  
 277 1.12) and in facilities serving <50 PLWHA (TR = 1.15; 95% CI: 1.09; 1.21).

278 The variables were then analyzed in the multiple models (Table 3). The time ratios of  
 279 individual and facility-related variables in the multiple models followed the same  
 280 direction as in the bivariate models.

281 **Table 3. Results of hierarchically adjusted multilevel models for time to VS,**  
 282 **according to individual and facility-related characteristics, Qualiaids-Brazil**  
 283 **Cohort, 2015-2018 (N = 128,360)**  
 284

Variable		TR (95% CI)
Model 1	<b>Sex</b>	
	Male	ref
Model 2	Female	0.91[0.90;0.92]
	<b>Age group (in years)</b>	
Model 1	15-19	1.14[1.11;1.16]
	20-29	1.08[1.07;1.10]
Model 2	30-39	1.06[1.04;1.07]
	40-49	1.03[1.02;1.05]
Model 1	50-59	Ref
	≥60	0.97[0.95;1.00]
<b>Race/skin color</b>		

<b>Model 3</b>	White	Ref	
	Black	1.04[1.02;1.05]	
	Yellow	1.01[0.97;1.06]	
	Brown	1.03[1.02;1.04]	
	Indigenous	1.17[1.07;1.27]	
	<b>Education (in years of schooling)</b>		
	None	1.18[1.14;1.21]	
	1-3	1.20[1.18;1.22]	
	4-7	1.15[1.14;1.16]	
	8-11	1.06[1.05;1.07]	
	≥12	Ref	
	<b>Initial therapeutic regimen</b>		
	Preferred regimen (2017-2018: NNRTI+1INI)	Ref	
	Preferred regimen (2015-2016: 2NRTI + 1NNRTI)	1.33[1.32;1.34]	
	Authorized special regimens	1.07[0.94;1.21]	
	Unauthorized regimens	1.23[1.16;1.31]	
	<b>Initial CD4 lymphocyte count (cells/mm<sup>3</sup>)</b>		
	≤200	1.09[1.08;1.10]	
	200-349	1.09[1.08;1.10]	
	350-499	1.04[1.03;1.05]	
	≥500	Ref	
	<b>Initial VL count (copies/mL)</b>		
	≤100,000	Ref	
	>100,000	1.19[1.17;1.20]	
	<b>Active tuberculosis episode until suppression</b>		
	No	Ref	
	Yes	1.10[1.08;1.12]	
	<b>Therapeutic regimen change</b>		
	No	Ref	
Yes	1.15[1.13;1.18]		
<b>Adherence</b>			
≥95%	Ref		
80-95%	1.19[1.18;1.21]		
<80%	1.83[1.79;1.86]		
<b>Geographic region</b>			
Central-West	1.18[1.08;1.28]		
North	1.20[1.11;1.30]		
Northeast	1.20[1.14;1.16]		
South	1.01[0.97;1.06]		
Southeast	Ref		
<b>Facility location (municipality)</b>			
Metropolitan region	Ref		
Other	1.06[1.02;1.10]		
<b>Number of patients served</b>			
≤50	1.15[1.05;1.26]		
51-500	0.96[0.89;1.04]		
>500	Ref		

285 Legend: Model 1 – sociodemographic characteristics; Model 2 – sociodemographic + clinical  
 286 characteristics; Model 3 – facility-related characteristics.  
 287 All models were adjusted for the number of VL tests performed until VS.

288 Among individual variables, the following were associated with longer time to VS: male

289 sex; age below 50 years; Black and Brown, race/skin color; education ≤11 years of



290 schooling; therapeutic regimen 2NRTI + 1NNRTI; authorized special regimens or  
 291 unauthorized regimens; initial CD4 count <500 cells/mm<sup>3</sup>; initial VL >100,000  
 292 copies/mL; active tuberculosis episode; therapeutic regimen change; and treatment  
 293 adherence <95%. Regarding the characteristics of treatment facilities, PLWHA who  
 294 received care in facilities in the North, Northeast, and Central-West regions had a  
 295 longer time to VS. The same was observed for PLWHA assisted by facilities located  
 296 outside the metropolitan region (TR = 1.06; 95% CI: 1.02; 1.10) and by facilities  
 297 attending <50 PLWHA (TR = 1.15; 95% CI: 1.05; 1.26).

298 Table 4 shows the difference in unexplained variability for each model. Model 2  
 299 showed the lowest unexplained variability, which is consistent with its higher number  
 300 of explanatory variables. The model adjusted for facility-related variables (model 3)  
 301 exhibited the lowest ICC (7.7%), indicating that this adjustment was able to reduce  
 302 heterogeneity in time to VS. Furthermore, it was observed that 16.2% of the variability  
 303 in time to VS was explained by individual sociodemographic and clinical variables  
 304 (model 2); however, 13.2% of this variability can be explained solely by the facility-  
 305 related variables. The log likelihood indicated that model 2 was the best fit.

306 **Table 4. Results of the random-effects analysis of models null through 3,**  
 307 **Qualiaids-Brazil Cohort, 2015-2018 (N = 128,360)**  
 308

	Null Model	Model 1	Model 2	Model 3
Random Variance	0.068	0.066	0.057	0.059
(SE)	(0.004)	(0.004)	(0.003)	(0.003)
ICC	0.093	0.091	0.083	0.077
PCV	ref	0.029	0.162	0.132
Log Likelihood	-712903.7	-712188.3	-706630.4	-712830.4

309 SE: standard error; ICC: intraclass correlation coefficient; PCV: proportional change in variance

310 The results of the sensitivity analyses were consistent with the findings, showing small  
 311 variations in effect estimates (Supplementary Tables 2 and 3).

## 312 Discussion

313 Among PLWHA participating in the Qualiaids-Brazil Cohort who initiated ART in SUS  
314 healthcare facilities between 2015 and 2018, nearly 90% achieved VS, half of whom  
315 did so within five months of treatment.

316 Individuals in the following categories had a higher proportion of VS during the cohort's  
317 time period: male sex, aged 50-59 years, white race/skin color, with  $\geq 12$  years of  
318 education, initial treatment regimen NNRTI+1INI, initial CD4 lymphocyte count  $\geq 500$   
319 cells/mm<sup>3</sup>, initial VL count  $\leq 100,000$  copies/mL, without an active tuberculosis  
320 episode, without therapeutic regimen change, with  $\geq 95\%$  adherence to treatment, and  
321 receiving clinical follow-up in facilities located in the Southeast or South regions, in  
322 metropolitan areas, and in facilities serving  $>500$  PLWHA.

323 Individual variables accounted for most of the variability in time to VS; however, facility-  
324 related variables also played a noteworthy role.

325 Regarding individual characteristics, there was an association with longer time to VS  
326 of individuals of brown and black race/skin color, as well as those with lower education  
327 levels. In Brazil, these characteristics are proxies for poorer social conditions[52]. This  
328 finding is consistent with several international studies on ethnic and social  
329 disparities[53-56].

330 Social issues are intertwined with clinical issues. The study demonstrated that late  
331 diagnosis, with a low CD4 level ( $<200$ ) and very high VL ( $>100,000$ ), delays time to  
332 VS, echoing numerous studies that associate these factors with negative outcomes.  
333 Since 2015, Brazil has maintained a late diagnosis proportion of around 25%[8]. The  
334 trends observed in countries with similar epidemic profiles also confirm the  
335 maintenance of late diagnosis proportions. Globally, it is still observed that the

336 proportion of people diagnosed late is changing little as the effectiveness of ART  
337 continues to improve[10,57-59].

338 In Brazil, especially, the second most important clinical condition associated with  
339 negative outcomes is tuberculosis (TB). This situation is similar to that of low-income  
340 countries, where TB is the leading cause of death among PLWHA, notably in the first  
341 year after diagnosis[60,61]. Brazil is among the 12 countries with the highest global  
342 TB burden. Regarding coinfection HIV and tuberculosis, it has the highest burden of  
343 those countries[62]. Coinfection with TB is associated with lower CD4 levels and  
344 higher VL levels, underscoring the importance of HIV treatment facilities in diagnosing  
345 and treating both latent and active tuberculosis [63,64].

346 The negative impact on time to VS resulting from poor adherence to HIV treatment  
347 reaffirms numerous studies that, since the HIV treatment became available, have  
348 emphasized the crucial role of promotion, monitoring, and support by treatment  
349 facilities for those with difficulty in adhering to the prescribed regimen [65,66].

350 The longer time to achieving VS among non-white individuals with lower education  
351 levels follows the general trend highlighted in studies of mortality, late diagnosis, loss  
352 to follow-up, and tuberculosis, reflecting social and ethnic inequality in the country.  
353 Despite significant progress in addressing the HIV epidemic through free and universal  
354 access to high-effectiveness care and medication across the country, the healthcare  
355 system has not successfully mitigated inequalities to achieved desired health  
356 outcomes, reflecting disparities in the allocation and organization of treatment  
357 facilities. The higher concentration of facilities in the Southeast and South regions and  
358 in metropolitan areas corresponds to the greater concentration of PLWHA in these  
359 locations. Certainly, there is also a need for smaller facilities, particularly in smaller

360 cities within the regions. On the other hand, the allocation of facilities in both large and  
361 small municipalities for a small number of patients (<50) appears to be problematic,  
362 suggesting significant diversity of HIV care policies among municipal  
363 administrations[28,67]. While certain geographical conditions may warrant the  
364 establishment of small-scale facilities, evidence repeatedly shows a higher likelihood  
365 of negative outcomes in facilities with a reduced number of patients [21,68]. Balancing  
366 easy access to treatment with professional training and organization therefore is an  
367 important priority to ensure appropriate quality of care. Disparities in the organization  
368 of HIV care at regional, district, and even municipal levels have been highlighted in  
369 national studies[31-34,69,70].

370 The study revealed a significant flaw in the quality of the care provided by treatment  
371 facilities: among PLWHA who achieved VS during the study period, 67.2% did not  
372 receive VL testing within the timeframe specified by the protocol (66 days)[38]. The  
373 deficiency in monitoring has been pointed out in studies of the records of two populous  
374 Brazilian states, Minas Gerais[24] and Rio de Janeiro[47]. The issue appears to be  
375 predominantly organizational in nature rather than caused by supply of tests since  
376 data indicate high and uniform availability of VL tests across the country's public  
377 service network [33, 34]. On the other hand, the request for VL tests and scheduling  
378 of follow-up appointments, lacks managerial mechanisms, such as electronic control  
379 of appointment scheduling and tests rather than relying on individual physician's  
380 request tests. We suggested that this flaw in monitoring, translated into longer-than-  
381 recommended intervals between tests, stems from the high demand for medical  
382 appointments—a common issue in larger facilities — thus influencing physicians'  
383 decisions regarding test and appointment scheduling. Another possibility is that the  
384 longer intervals may be a recommendation from facility managers to alleviate the

385 pressure of demand for appointments. Detailed studies focusing on the organizational  
386 processes in treatment facilities are needed to support interventions capable of  
387 improving this situation as quickly as possible.

388 Promptness in having the first VL test after treatment initiation is fully justified by the  
389 clinical need for timely detection of viral failures and adherence issues[1,71]. It may  
390 also operate as an incentive to maintain adherence for those who achieve rapid  
391 VS[72,73]. Proper VL monitoring and rapid VS rate are indicators of quality of care[12].

392 The ability to quickly achieve VS is feasible given the effectiveness of available ART  
393 regimen, especially for those who initiate treatment with CD4>200 and low VL and  
394 maintain good adherence. ART effectiveness has increased with widespread use of  
395 regimens containing integrase inhibitors, especially dolutegravir [74], which is part of  
396 the recommended regimen for treatment initiation in Brazil. There is also repeated  
397 evidence that rapid treatment initiation accelerates time to VS[75,76]. However, the  
398 time to initiation could not be addressed in this study.

399 The median time to VS was 55 days for those who had the first VL test after starting  
400 treatment within the established timeframe (66 days). The median is similar to that  
401 found in observational studies conducted in locations with a comparable epidemic  
402 profile to Brazil's (concentrated epidemic) and with free access to treatment, such as  
403 Atlanta, 2016 (57 days)[77], and London, 2018 (56 days)[78].

404 Considering the importance of rapid suppression, Xia[54] and Dombrowski[12]  
405 suggested that the treatment time parameter for estimating the "suppressed" bar of  
406 the cascade—usually set at 12 months or, as in Brazil, at six months—be reduced to  
407 three months. They argue that rapid initiation and the high efficacy of current ART  
408 shorten this time, as exemplified by studies that, using a VL threshold of <200

409 copies/mL in three months, found VS proportions of 37%[54] and 45%[17]. With a  
410 lower threshold of <50 copies/mL, the proportion of those who achieved VS, in this  
411 study, within the shortest evaluated interval (66 days - 27.5%) would likely be higher  
412 if the monitoring protocol had been adhered to for most PLWHA. Among all those who  
413 achieved VS and were tested within the first three months, VS rate was 36.1%,  
414 indicating that it would be possible in Brazil to shorten the threshold to three months,  
415 even as an incentive for improving VL monitoring.

416 This study was the first nationwide cohort, based on a longitudinal database, that  
417 analyzed time to VS in PLWHA receiving treatment in the SUS. It was also one of the  
418 largest operational cohorts in the international literature. The inclusion of the  
419 characteristics of healthcare facilities in the analyses reinforces the study's originality.

420 As time to VS may be influenced by the number of VL tests conducted during the  
421 period, the inclusion of this variable in the analyses is also a strength to be noted.

422 Nonetheless, there are were limitations to our analysis. First, in the studied database  
423 there was no explicit definition of the healthcare system in which PLWHA received  
424 care. Thus, a previously published standardized classification strategy, as defined in  
425 the methods section, was employed to minimize that limitation. It should also be noted  
426 that the use of secondary sources such as developed for operational purposes,  
427 involves inconsistencies and missing data, which may lead to misclassification errors  
428 and underestimation of the measures of interest. However, the definition of inclusion  
429 criteria sensitive to potential inconsistencies and the imputation of data for relevant  
430 variables reduces the possibility of interference in the results [29].

431 This study of a large cohort of PLWA in Brazil was the first to analyze time to viral  
432 suppression and the first to include characteristics of healthcare facilities. The results

433 strongly suggest the need for more comprehensive longitudinal studies, including  
434 more individual and health facilities characteristics, that can further contribute to  
435 healthcare policies for PLWHA in Brazil.

436 While acknowledging the limitations, the findings seem sufficient to indicate the  
437 urgency of improving VL monitoring in the treatment facilities network across the  
438 country. This must be carried out as part of a coordinated effort to provide more  
439 equitable access and capacity for HIV facilities to optimize quality care and reduce  
440 time to viral suppression.

441 the quality of care provided to PLWHA nationwide.

## 442 **References**

- 443 1. INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund  
444 B, Sharma S, et.al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV  
445 Infection. *N Engl J Med*. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816.
- 446 2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N,  
447 et.al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med*.  
448 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693.
- 449 3. Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV  
450 infection: undetectable equals untransmittable. *Jama*. 2019 Feb 5;321(5):451-2
- 451 4. Broyles LN, Luo R, Boeras D, Vojnov L. (2023). The risk of sexual transmission of HIV  
452 in individuals with low-level HIV viraemia: a systematic review. *Lancet* (London,  
453 England), 402(10400), 464–471. [https://doi.org/10.1016/S0140-6736\(23\)00877-2](https://doi.org/10.1016/S0140-6736(23)00877-2)
- 454 5. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of  
455 engagement in HIV care and its relevance to test-and-treat strategies for prevention of  
456 HIV infection. *Clin Infect Dis*. 2011;52:793–800. doi: 10.1093/cid/ciq243
- 457 6. Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum:  
458 updates, goals, and recommendations for the future. *AIDS Res Ther*. 2016 Nov  
459 8;13:35. doi: 10.1186/s12981-016-0120-0. PMID: 27826353; PMCID: PMC5100316.



- 460 7. World Health Organization. Regional Office for the Eastern Mediterranean. (2014). HIV  
461 test–treat–retain cascade analysis: guide and tools. World Health Organization.  
462 Regional Office for the Eastern Mediterranean.  
463 <https://iris.who.int/handle/10665/250533>
- 464 8. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente.  
465 Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente  
466 Transmissíveis (DATHI). Relatório do Monitoramento Clínico do HIV 2022, Brasília -  
467 DF 2023
- 468 9. Haber N, Pillay D, Porter K, Bärnighausen T. (2016). Constructing the cascade of HIV  
469 care: methods for measurement. *Current opinion in HIV and AIDS*, 11(1), 102–108.  
470 <https://doi.org/10.1097/COH.0000000000000212>
- 471 10. Crepaz N, Ruiguang SO, HALL HI. Estimated time from HIV infection to diagnosis and  
472 diagnosis to first viral suppression during 2014–2018. *AIDS (London, England)*. 2021  
473 Nov 11;35(13):2181.
- 474 11. Vourli G, Katsarolis I, Pantazis N, Touloumi G. HIV continuum of care: expanding  
475 scope beyond a cross-sectional view to include time analysis: a systematic review.  
476 *BMC Public Health* 21, 1699 (2021). <https://doi.org/10.1186/s12889-021-11747-z>
- 477 12. Dombrowski JC, Baeten JM. It's Time to Make the Time to Viral Suppression After HIV  
478 Diagnosis a Metric of HIV Care Success. *J Infect Dis*. 2019;219(6):845-847.  
479 [doi:10.1093/infdis/jiy539](https://doi.org/10.1093/infdis/jiy539)
- 480 13. Shoemaker ES, Becker ML, Liddy CE, McClarty LM, Asghari S, Hurd J, et.al. Creating  
481 clinical cohorts: challenges encountered in two Canadian provinces. *Healthc Policy*.  
482 2019;15(1):10–8.
- 483 14. Liu J, Wilton J, Sullivan A, Marchand-Austin A, Rachlis B, Giles M, et.al. Ontario HIV  
484 Epidemiology and Surveillance Initiative (2019). Cohort profile: Development and  
485 profile of a population-based, retrospective cohort of diagnosed people living with HIV  
486 in Ontario, Canada (Ontario HIV Laboratory Cohort). *BMJ open*, 9(5), e027325.  
487 <https://doi.org/10.1136/bmjopen-2018-027325>



- 488 15. Bacon O, Chin J, Cohen SE, Hessel NA, Sachdev D, et.al. Decreased Time From  
489 Human Immunodeficiency Virus Diagnosis to Care, Antiretroviral Therapy Initiation,  
490 and Virologic Suppression during the Citywide RAPID Initiative in San Francisco. *Clin*  
491 *Infect Dis*. 2021 Jul 1;73(1):e122-e128. doi: 10.1093/cid/ciaa620
- 492 16. Nanditha NGA, Dong X, Tafessu HM, Wang L, Lu M, Barrios R, et.al. (2022). A  
493 province-wide HIV initiative to accelerate initiation of treatment-as-prevention and  
494 virologic suppression in British Columbia, Canada: a population-based cohort study.  
495 *CMAJ open*, 10(1), E27–E34. <https://doi.org/10.9778/cmajo.20210093>
- 496 17. Alejos B, Díez C, Galindo MJ, López JC, Moreno-García E, Estrada V, et.al. (2022).  
497 Progress in the quality of care for newly diagnosed people with HIV in Spain (2004-  
498 2019). *Antiviral therapy*, 27(4), <https://doi.org/10.1177/13596535221112729>
- 499 18. Pyngottu A, Scherrer AU, Kouyos R, Huber M, Hirsch H, Perreau M, et.al. Swiss HIV  
500 Cohort Study. Predictors of Virological Failure and Time to Viral Suppression of First-  
501 Line Integrase Inhibitor-Based Antiretroviral Treatment. *Clin Infect Dis*. 2021 Oct  
502 5;73(7):e2134-e2141. doi: 10.1093/cid/ciaa1614.
- 503 19. Huang SW, Shen MC, Wang WH, Li WY, Wang JH, Tseng CY, et.al. High prevalence  
504 of HIV-1 transmitted drug resistance and factors associated with time to virological  
505 failure and viral suppression in Taiwan. *J Antimicrob Chemother*. 2021 Dec  
506 24;77(1):185-195. doi: 10.1093/jac/dkab361.
- 507 20. Monroe AK, Happ LP, Rayeed N, Ma Y, Jaurrette MJ, Terzian AS, et.al. Clinic-Level  
508 Factors Associated With Time to Antiretroviral Initiation and Viral Suppression in a  
509 Large, Urban Cohort. *Clin Infect Dis*. 2020 Oct 23;71(7):e151-e158. doi:  
510 10.1093/cid/ciz1098.
- 511 21. Wiewel EW, Borrell LN, Jones HE, Maroko AR, Torian LV. (2019). Healthcare facility  
512 characteristics associated with achievement and maintenance of HIV viral suppression  
513 among persons newly diagnosed with HIV in New York City. *AIDS care*, 31(12), 1484–  
514 1493. <https://doi.org/10.1080/09540121.2019.1595517>

- 515 22. Badejo O, Noestlinger C, Jolayemi T, Adeola J, Okonkwo P, Van Belle S, et.al.  
516 Multilevel modelling and multiple group analysis of disparities in continuity of care and  
517 viral suppression among adolescents and youths living with HIV in Nigeria. *BMJ Glob*  
518 *Health*. 2020 Nov;5(11):e003269. doi: 10.1136/bmjgh-2020-003269
- 519 23. Sarrazin VMS, Ohl ME, Richardson KK, Asch SM, Gifford AL, Bokhour BG. (2018).  
520 Patient and Facility Correlates of Racial Differences in Viral Control for Black and White  
521 Veterans with HIV Infection in the Veterans Administration. *AIDS patient care and*  
522 *STDs*, 32(3), 84–91. <https://doi.org/10.1089/apc.2017.0213>
- 523 24. Mendicino CCP, Silva GJD, Braga LP, Colosimo EA, Guimarães MDC, Pádua CA M.  
524 (2020). Monitoring HIV infection in Minas Gerais state: 15-year assessment of adults  
525 living with HIV initiating Antiretroviral Therapy. *Revista da Sociedade Brasileira de*  
526 *Medicina Tropical*, 53, e20200360. <https://doi.org/10.1590/0037-8682-0360-2020>
- 527 25. Greco DB, Simão M. Brazilian policy of universal access to AIDS treatment:  
528 sustainability challenges and perspectives. *AIDS*. (2007) Jul;21 Suppl 4:S37-45. doi:  
529 10.1097/01.aids.0000279705.24428.a3
- 530 26. Basso CR. Programa de DST/AIDS no SUS. In: Negri B, Viana ALD, organizadores.  
531 *O Sistema Único de Saúde em 10 anos de desafio*. São Paulo: Sobravime; 2002. p.  
532 43-58
- 533 27. Castro MC, Massuda A, Almeida G, Menezes-Filho NA, Andrade MV, de Souza  
534 Noronha KVM, et.al. Brazil's unified health system: the first 30 years and prospects for  
535 the future. *The Lancet*. 2019 Jul 27;394(10195):345-356. doi: 10.1016/S0140-  
536 6736(19)31243-7. Epub 2019 Jul 11
- 537 28. Alves AM, Santos ACD, Kumow A, Sato APS, Helena ETS, Nemes MIB. Beyond  
538 access to medication: the role of SUS and the characteristics of HIV care in Brazil. *Rev*  
539 *Saude Publica*. 2023 Apr 17;57:26. doi: 10.11606/s1518-8787.2023057004476. PMID:  
540 37075422; PMCID: PMC10118421.
- 541 29. Sato APS, Nemes MIB, Alves AM, Souza EL, Santos BDR, Nunes LO, et.al. Profile of  
542 the cohort of people being treated for HIV infection in the SUS, Brazil, 2015-2018. *Rev*

- 543 Saude Publica. 2023 Oct 20;57:66. doi: 10.11606/s1518-8787.2023057005256. PMID:  
544 37878852; PMCID: PMC10519680.
- 545 30. Nemes MIB, Castanheira ERL, Loch AP, Santos MA, Alves AM, Melchior R, et al.  
546 Avaliação de serviços de saúde: a experiência do Qualiaids. In: Akerman M, Furtado  
547 JP, organizadores. Práticas de avaliação em saúde no Brasil – Diálogos. Porto Alegre,  
548 RS: Rede Unida; 2016 [citado 12 nov 2021]. p. 92-145. Available on:  
549 [http://historico.redeunida.org.br/editora/biblioteca-digital/serie-atencao-basica-e-](http://historico.redeunida.org.br/editora/biblioteca-digital/serie-atencao-basica-e-educacao-na-saude/praticas-de-avaliacao-em-saude-no-brasil-dialogos-pdf)  
550 [educacao-na-saude/praticas-de-avaliacao-em-saude-no-brasil-dialogos-pdf](http://historico.redeunida.org.br/editora/biblioteca-digital/serie-atencao-basica-e-educacao-na-saude/praticas-de-avaliacao-em-saude-no-brasil-dialogos-pdf)
- 551 31. Melchior R, Nemes MIB, Basso CR, Castanheira ERL, Alves MTSSB, Buchala CM, et  
552 al. Evaluation of the organizational structure of HIV/AIDS outpatient care in Brazil. Rev  
553 Saude Publica. 2006;40(1):143-51. [https://doi.org/10.1590/S0034-](https://doi.org/10.1590/S0034-89102006000100022)  
554 [89102006000100022](https://doi.org/10.1590/S0034-89102006000100022)
- 555 32. Nemes MIB, Alves AM, Loch AP. Sistema de avaliação Qualiaids. São Paulo:  
556 Faculdade de Medicina da USP, Departamento de Medicina Preventiva; 2016 [cited  
557 on May 2024]. Available on: <https://equipequaliaids.wixsite.com/qualiaids>
- 558 33. Nemes MIB, Alencar TMD, Basso CR, Castanheira ERL, Melchior R, Alves MTSSB,  
559 et al. Assessment of outpatient services for AIDS patients, Brazil: comparative study  
560 2001/2007. Rev Saude Publica. 2013;47(1):137-46. [https://doi.org/10.1590/S0034-](https://doi.org/10.1590/S0034-89102013000100018)  
561 [89102013000100018](https://doi.org/10.1590/S0034-89102013000100018)
- 562 34. Loch AP, Nemes MIB, Santos MA, Alves AM, Melchior R, Basso CR, et al. Evaluation  
563 of outpatient services in the Brazilian Unified National Health System for persons living  
564 with HIV: a comparison of 2007 and 2010. Cad Saúde Pública [Internet].  
565 2018;34(2):e00047217. Available on: <https://doi.org/10.1590/0102-311X00047217>
- 566 35. Buchbinder SP, Havlir DV. Getting to Zero San Francisco: A Collective Impact  
567 Approach. J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3(Suppl 3):S176-S182.  
568 doi: 10.1097/QAI.0000000000002200.

- 569 36. The Late Presentation Working Groups in Euro SIDA and COHERE. Estimating the  
570 burden of HIV late presentation and its attributable morbidity and mortality across  
571 Europe 2010–2016. *BMC Infect Dis* 20, 728 (2020)
- 572 37. Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, et.al. Long-term trends in  
573 CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy:  
574 UK Collaborative HIV Cohort (CHIC) study. *HIV Med.* 2011 Nov;12(10):583-93. doi:  
575 10.1111/j.1468-1293.2011.00929.x.
- 576 38. Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de  
577 Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do  
578 HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para  
579 Manejo da Infecção pelo HIV em Adultos. Brasília (DF); 2018 [citado 1 nov 2021].  
580 Available on: [http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-](http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos)  
581 [terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos](http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos)
- 582 39. Colosimo EA, Giolo S. Análise de sobrevivência aplicada. São Paulo: Blucher, c2006.  
583 367p
- 584 40. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression  
585 model in survival analysis. *Stat Med.* 1992 Oct-Nov;11(14-15):1871-9. doi:  
586 10.1002/sim.4780111409
- 587 41. Birhan H, Derebe K, Muche S, Melese B. Statistical Analysis on Determinant Factors  
588 Associated with Time to Death of HIV/TB Co-Infected Patients Under HAART at Debre  
589 Tabor Referral Hospital: An Application of Accelerated Failure Time-Shared Frailty  
590 Models. *HIV AIDS (Auckl).* 2021 Jul 17; 13:775-787. doi: 10.2147/HIV.S319745.
- 591 42. Merlo J, Chaix B, Yang M, Lynch J, Råstam L. A brief conceptual tutorial of multilevel  
592 analysis in social epidemiology: linking the statistical concept of clustering to the idea  
593 of contextual phenomenon. *J Epidemiol Community Health.* 2005 Jun;59(6):443-9. doi:  
594 10.1136/jech.2004.023473.
- 595 43. Merlo J, Yang M, Chaix B, Lynch J, Råstam L. A brief conceptual tutorial on multilevel  
596 analysis in social epidemiology: investigating contextual phenomena in different

- 597 groups of people. *J Epidemiol Community Health*. 2005 Sep;59(9):729-36. doi:  
598 10.1136/jech.2004.023929.
- 599 44. Merlo J, Chaix B, Ohlsson H, Beckman A, Johnell K, Hjerpe Pet.al. A brief conceptual  
600 tutorial of multilevel analysis in social epidemiology: using measures of clustering in  
601 multilevel logistic regression to investigate contextual phenomena. *J Epidemiol  
602 Community Health*. 2006 Apr;60(4):290-7. doi: 10.1136/jech.2004.029454.
- 603 45. Tesema GA, Mekonnen TH, Teshale AB. (2020) Individual and community-level  
604 determinants, and spatial distribution of institutional delivery in Ethiopia, 2016: Spatial  
605 and multilevel analysis. *PLoS ONE* 15(11): e0242242.
- 606 46. Lubega P, Nalugya SJ, Kimuli AN, Twinokusiima M, Khasalamwa M, Kyomugisa R,  
607 et.al. Adherence to viral load testing guidelines, barriers, and associated factors among  
608 persons living with HIV on ART in Southwestern Uganda: a mixed-methods study.  
609 *BMC Public Health*. 2022 Jun 29;22(1):1268. doi: 10.1186/s12889-022-13674-z.
- 610 47. Bocage AE, Coelho LE, Lake JE, Clark JL, Torres TS, Jalil EM,et al. The Impact of  
611 COVID-19 on HIV Care in Rio de Janeiro, Brazil 2019–2021: Disparities by Age and  
612 Gender. *AIDS Behav* (2023). <https://doi.org/10.1007/s10461-023-03988-3>
- 613 48. Costa JM, Torres TS, Coelho LE, Luz PM. Adherence to antiretroviral therapy for  
614 HIV/AIDS in Latin America and the Caribbean: Systematic review and meta-analysis.  
615 *J Int AIDS Soc*. 2018 Jan;21(1):e25066. doi: 10.1002/jia2.25066
- 616 49. Harlow AF, Bor J, Brennan AT, Maskew M, MacLeod W, Carmona S, et.al. Impact of  
617 Viral Load Monitoring on Retention and Viral Suppression: A Regression Discontinuity  
618 Analysis of South Africa's National Laboratory Cohort. *Am J Epidemiol*. 2020 Dec  
619 1;189(12):1492-1501. doi: 10.1093/aje/kwaa140
- 620 50. Hall HI, Tang T, Westfall AO, Mugavero MJ. (2013). HIV care visits and time to viral  
621 suppression, 19 U.S. jurisdictions, and implications for treatment, prevention and the  
622 national HIV/AIDS strategy. *PloS one*, 8(12), e84318.  
623 <https://doi.org/10.1371/journal.pone.0084318>

- 624 51. Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC. The effect on treatment comparisons  
625 of different measurement frequencies in human immunodeficiency virus observational  
626 databases. *Am J Epidemiol*. 2006 Apr 1;163(7):676-83. doi: 10.1093/aje/kwj083. Epub  
627 2006 Feb 16. PMID: 16484448.
- 628 52. Feller DJ, Agins BD. (2017). Understanding Determinants of Racial and Ethnic  
629 Disparities in Viral Load Suppression. *Journal of the International Association of*  
630 *Providers of AIDS Care*, 16(1), 23–29. <https://doi.org/10.1177/2325957416667488>
- 631 53. Flynn AG, Anguzu G, Mubiru F, Kiragga AN, Kanya M, Meya DB, et.al. Socioeconomic  
632 position and ten-year survival and virologic outcomes in a Ugandan HIV cohort  
633 receiving antiretroviral therapy. *PLoS One*. 2017 Dec 15;12(12):e0189055. doi:  
634 10.1371/journal.pone.0189055. PMID: 29244807; PMCID: PMC5731768.
- 635 54. Xia Q, Robbins RS, Lazar R, Torian LV, Braunstein SL. Racial and socioeconomic  
636 disparities in viral suppression among persons living with HIV in New York City. *Ann*  
637 *Epidemiol*. 2017 May;27(5):335-341. doi: 10.1016/j.annepidem.2017.04.005.
- 638 55. López JD, Qiao Q, Presti RM, Hammer RA, Foraker RE. The impact of neighborhood  
639 socioeconomic status on retention in care and viral suppression among people living  
640 with HIV. *AIDS Care*. 2022 Nov;34(11):1383-1389. doi:  
641 10.1080/09540121.2022.2040724. Epub 2022 Feb 14. PMID: 35164602.
- 642 56. Tymejczyk O, Jamison K, Pathela P, Braunstein S, Schillinger JA, Nash D. HIV Care  
643 and Viral Load Suppression After Sexual Health Clinic Visits by Out-of-Care HIV-  
644 Positive Persons. *AIDS Patient Care STDS*. 2018 Oct;32(10):390-398. doi:  
645 10.1089/apc.2018.0097. PMID: 30277815; PMCID: PMC6198765.
- 646 57. Mocroft A, Lundgren J, Antinori A, Monforte AD, Brännström J, Bonnet F, et al. Late  
647 presentation for HIV care across Europe: update from the Collaboration of  
648 Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.  
649 *Euro Surveill*. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30070.
- 650 58. UNAIDS, Global AIDS Uptade – Seizing the moment. Tackling entrenched inequalities  
651 to end epidemics. Geneve, 2020..

- 652 59. Rodrigues A, Struchiner CJ, Coelho LE, Veloso VG, Grinsztejn B, et al. (2021). Late  
653 initiation of antiretroviral therapy: inequalities by educational level despite universal  
654 access to care and treatment. *BMC Public Health*, 21 (1), S. 389.  
655 <http://doi.org/10.1186/s12889-021-10421-8>
- 656 60. Barr DA, Lewis JM, Feasey N, Schutz C, Kerkhoff AD, Jacob, ST, et al. Mycobacterium  
657 tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in  
658 seriously ill adults with HIV: a systematic review and meta-analysis of individual patient  
659 data. *Lancet Infect Dis*. 2020;20(6):742-752. doi:10.1016/S1473-3099(19)30695-4.
- 660 61. dos Santos DT, Arroyo LH, Alves YM, Alves LS, Berra TZ, Crispim JA, et al. Survival  
661 time among patients who were diagnosed with tuberculosis, the precocious deaths and  
662 associated factors in southern Brazil. *Trop Med Health*. 2021;49(1):31. Published 2021  
663 Apr 21. doi:10.1186/s41182-021-00320-4
- 664 62. World Health Organization. Global tuberculosis report 2021. Geneva: World Health  
665 Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO
- 666 63. Magnabosco GT, Lopes LM, Andrade RL de P, Brunello MEF, Monroe AA, Villa TCS.  
667 Tuberculosis control in people living with HIV/AIDS. *Rev Latino-Am Enfermagem*  
668 [Internet]. 2016;24:e2798. Available from: [https://doi.org/10.1590/1518-](https://doi.org/10.1590/1518-8345.1187.2798)  
669 [8345.1187.2798](https://doi.org/10.1590/1518-8345.1187.2798)
- 670 64. Saraceni V, Benzaken AS, Pereira G, Andrade KB, Oliveira PB, Arakaki-Sanchez D,  
671 et.al. (2018). Tuberculosis burden on AIDS in Brazil: A study using linked databases.  
672 *PloS one*, 13(11), e0207859. <https://doi.org/10.1371/journal.pone.0207859>.
- 673 65. Cutrell J, Jodlowski T, Bedimo R. The management of treatment-experienced HIV  
674 patients (including virologic failure and switches). *Ther Adv Infect Dis*.  
675 2020;7:2049936120901395. Published 2020 Jan 20. doi:10.1177/2049936120901395
- 676 66. McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-World Adherence  
677 to Antiretroviral Therapy Among HIV-1 Patients Across the United States. *Adv Ther*.  
678 2021 Sep;38(9):4961-4974. doi: 10.1007/s12325-021-01883-8. Epub 2021 Aug 14.



- 679 67. Nemes MIB, Alves AM. Relatório Qualiaids 2017. Sistema de avaliação Qualiaids. São  
680 Paulo: Faculdade de Medicina da USP, Departamento de Medicina Preventiva; 2016  
681 [cited on May 2023]. Available on:  
682 <https://equipequaliaids.wixsite.com/qualiaids/publica%C3%A7%C3%B5es>
- 683 68. O'Neill M, Karelak GD, Feller DJ, Knudsen-Strong E, Lajeunesse D, et.al. (2015). The  
684 HIV Workforce in New York State: Does patient volume Correlate with quality? *Clinical*  
685 *Infectious Diseases*, 61(12),1871–1877.
- 686 69. Nemes MIB, Castanheira ERL, Melchior R, Alves MTSSB, Basso CR. (2004).  
687 Avaliação da qualidade da assistência no programa de AIDS: questões para a  
688 investigação em serviços de saúde no Brasil. *Cadernos de Saúde Pública*, 20(Suppl.  
689 2), S310-S321. <https://dx.doi.org/10.1590/S0102-311X2004000800024>
- 690 70. Nemes MIB, Melchior R, Basso CR, Castanheira ERL, Alves MTSSB, Conway S. The  
691 variability and predictors of quality of AIDS care services in Brazil. *BMC Health Serv*  
692 *Res* 9, 51 (2009). <https://doi.org/10.1186/1472-6963-9-51>
- 693 71. Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, et.al. Viremia copy-  
694 years predicts mortality among treatment-naive HIV-infected patients initiating  
695 antiretroviral therapy. *Clin Infect Dis*. 2011 Nov;53(9):927-35. doi: 10.1093/cid/cir526.  
696 Epub 2011 Sep 2. PMID: 21890751; PMCID: PMC3189165.
- 697 72. World Health Organization. The role of HIV viral suppression in improving individual  
698 health and reducing transmission: policy brief. ISBN 978-92-4-005517-9 electronic  
699 version. © World Health Organization 2023
- 700 73. Bouabida K, Chaves BG, Anane E. Challenges and barriers to HIV care engagement  
701 and care cascade: viewpoint. *Front Reprod Health*. 2023 Jul 20;5:1201087. doi:  
702 10.3389/frph.2023.1201087.
- 703 74. Meireles MV, Pascom ARP, Duarte EC, McFarland W. Comparative effectiveness of  
704 first-line antiretroviral therapy: results from a large real-world cohort after the  
705 implementation of dolutegravir. *AIDS*. 2019 Aug 1;33(10):1663-1668. doi:  
706 10.1097/QAD.0000000000002254.



- 707 75. Michienzi SM, Barrios M, Badowski ME. Evidence Regarding Rapid Initiation of  
708 Antiretroviral Therapy in Patients Living with HIV. *Curr Infect Dis Rep* 23, 7 (2021).  
709 <https://doi.org/10.1007/s11908-021-00750-5>
- 710 76. Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, et.al.  
711 Virologic outcomes in early antiretroviral treatment: HPTN 052. *HIV Clin Trials*. 2017  
712 May;18(3):100-109. doi: 10.1080/15284336.2017.1311056. Epub 2017 Apr 7.
- 713 77. Colasanti J, Sumitani J, Mehta CC, Zhang Y, Nguyen ML, Del Rio C, Armstrong WS.  
714 Implementation of a Rapid Entry Program Decreases Time to Viral Suppression  
715 Among Vulnerable Persons Living With HIV in the Southern United States. *Open*  
716 *Forum Infect Dis*. 2018 Jun 28;5(6):ofy104. doi: 10.1093/ofid/ofy104. PMID: 29992172;  
717 PMCID: PMC6022569.
- 718 78. Girometti N, Lander F, McOwan A, Nwokolo N, Boffito M, Whitlock G. and (2020),  
719 Rapid ART start in early HIV infection: Time to viral load suppression and retention in  
720 care in a London cohort. *HIV Med*, 21: 613-615. <https://doi.org/10.1111/hiv.12900>
- 721 79. Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S. Viral load monitoring for  
722 people living with HIV in the era of test and treat: progress made and challenges ahead  
723 - a systematic review. *BMC Public Health*. 2022 Jun 16;22(1):1203. doi:  
724 10.1186/s12889-022-13504-2. PMID: 35710413; PMCID: PMC9202111.




Figure 1





Figure2



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.30.24308200>; this version posted May 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Number of facilities ranked by size	Central-West		Northeast		North		Southeast		South		Total	
	n	%	n	%	n	%	n	%	n	%	n	%
Up to 50 persons	6	15.0	33	26.8	8	17.8	306	55.1	44	24.7	397	42.2
51 to 500 persons	27	67.5	72	58.5	28	62.2	219	39.5	115	64.6	461	49.0
More than 500 persons	7	17.5	18	14.6	9	20.0	30	5.4	19	10.7	83	8.8
<b>Total</b>	<b>40</b>	<b>100.0</b>	<b>123</b>	<b>100.0</b>	<b>45</b>	<b>100.0</b>	<b>555</b>	<b>100.0</b>	<b>178</b>	<b>100.0</b>	<b>941</b>	<b>100.0</b>

Figure3